Therapeutic potential of fluoxetine in neurological disorders.
about
Fluoxetine for multiple sclerosisRoles of cocaine- and amphetamine-regulated transcript in the central nervous systemQuetiapine fumarate for the treatment of multiple sclerosis: focus on myelin repair.Reversal of hippocampal neuronal maturation by serotonergic antidepressants.Antidepressant treatment response is modulated by genetic and environmental factors and their interactions.Implications and limitations of cellular reprogramming for psychiatric drug development.Molecular Advances Leading to Treatment Implications for Fragile X Premutation CarriersNeuron-astrocyte interactions in neurodegenerative diseases: Role of neuroinflammationPatterns of serotonergic antidepressant usage in prodromal Huntington diseaseDepression: a repair response to stress-induced neuronal microdamage that can grade into a chronic neuroinflammatory condition?Neuromuscular stimulation after stroke: from technology to clinical deployment.Subacute fluoxetine enhances conditioned responding and conditioning-specific reflex modification of the rabbit nictitating membrane response: implications for drug treatment with selective serotonin reuptake inhibitors.Fluoxetine increases hippocampal neurogenesis and induces epigenetic factors but does not improve functional recovery after traumatic brain injury.Fluoxetine in progressive multiple sclerosis (FLUOX-PMS): study protocol for a randomized controlled trial.Chemotherapy and cognitive impairment: treatment options.Treatment trials in progressive MS--current challenges and future directions.Selective Serotonin Reuptake Inhibitors for Treating Neurocognitive and Neuropsychiatric Disorders Following Traumatic Brain Injury: An Evaluation of Current Evidence.Prenatal stress and early-life exposure to fluoxetine have enduring effects on anxiety and hippocampal BDNF gene expression in adult male offspring.Transforming Growth Factor-Beta Signaling in the Neural Stem Cell Niche: A Therapeutic Target for Huntington's Disease.Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets.Neuroligin modulates the locomotory dopaminergic and serotonergic neuronal pathways of C. elegans.Profiling of hypothalamic and hippocampal gene expression in chronically stressed rats treated with St. John's wort extract (STW 3-VI) and fluoxetine.3,5,6,7,8,3',4'-Heptamethoxyflavone, a Citrus Flavonoid, Ameliorates Corticosterone-Induced Depression-like Behavior and Restores Brain-Derived Neurotrophic Factor Expression, Neurogenesis, and Neuroplasticity in the Hippocampus.Piperine potentiates the effects of trans-resveratrol on stress-induced depressive-like behavior: involvement of monoaminergic system and cAMP-dependent pathway.Perspective: Neuroregenerative Nutrition.Both chronic treatments by epothilone D and fluoxetine increase the short-term memory and differentially alter the mood status of STOP/MAP6 KO mice.Long-term Ameliorative Effects of the Antidepressant Fluoxetine Exposure on Cognitive Deficits in 3 × TgAD Mice.Regulation of astrocyte pathology by fluoxetine prevents the deterioration of Alzheimer phenotypes in an APP/PS1 mouse model.Attention-deficit hyperactivity disorder and intellectual disability: a study of association with brain-derived neurotrophic factor gene polymorphisms.
P2860
Q24198247-1AE03291-D3FB-48D5-96A6-9FA12A46658EQ28252842-0638EAC9-BB1B-48ED-B23A-3134EF9C481FQ30656233-608271F1-2D5B-43D3-9F54-F3B0089FAADEQ33929389-56EE1214-0A17-443D-A5F3-75FF275E6EBCQ33930731-DDEA6568-B0D5-46B7-9F21-9085C2F20771Q34385134-1F10AFBD-EC60-41F4-ABF5-47E93E7FAF6CQ34575595-E16B2281-E85A-443A-86CD-87C333B7A210Q36238937-4A3B2B63-22FE-47A7-B133-396518A55B7BQ37148863-BCBE6AC7-A659-49CA-81A4-F583EBCD1B43Q37183514-3BD1EE98-54A8-415C-91B3-C2452E2CA667Q37432201-3AE5D57D-6761-4E08-9B28-A530319C8F41Q37494744-6F8AAA11-8315-42C4-8F67-84AAFC81617BQ37550380-67199995-EF71-49C2-BDBF-A5094D8281FDQ37597918-934F4D92-DC76-4BAA-A718-C9035436D386Q37911248-A3B31BED-D016-4A06-AECC-6179CAF72122Q38125123-EF779DF8-7562-4656-8B14-B1477DE61BC3Q38649590-6BAC625E-3B22-4D97-9756-5AA13D9FBCA0Q40274241-E1AAE23D-D0A0-444A-BF2F-20D1E4D6728AQ41821958-13156FE5-4E41-41AB-84A6-C27A3721346BQ42097305-E685CF0B-B359-47F7-82AE-B67DA78A1829Q42446057-E65FB4D3-64DD-4443-928A-4D25DEC82649Q42868931-DCA06612-2429-41E8-AFB0-AC5707752A3AQ48057024-DAF5883A-0E05-41AC-9670-551327D7F7F0Q48061914-DAEC1E70-0EFE-468B-8C9B-898E6CA10010Q48194917-B5A2F5D8-F600-464B-9C8B-6C7D71D85C65Q48362489-41BDB700-A262-4764-908B-CF01B78194EEQ48664940-2F352BF2-3953-4968-AAC3-EECEF9188834Q50556703-4AEAB119-D80B-4353-851C-FEEF8A5A0C04Q51034231-20AE50EA-3D83-42B7-8F32-F5B7B63C74EF
P2860
Therapeutic potential of fluoxetine in neurological disorders.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Therapeutic potential of fluoxetine in neurological disorders.
@ast
Therapeutic potential of fluoxetine in neurological disorders.
@en
Therapeutic potential of fluoxetine in neurological disorders.
@nl
type
label
Therapeutic potential of fluoxetine in neurological disorders.
@ast
Therapeutic potential of fluoxetine in neurological disorders.
@en
Therapeutic potential of fluoxetine in neurological disorders.
@nl
prefLabel
Therapeutic potential of fluoxetine in neurological disorders.
@ast
Therapeutic potential of fluoxetine in neurological disorders.
@en
Therapeutic potential of fluoxetine in neurological disorders.
@nl
P2093
P2860
P1476
Therapeutic potential of fluoxetine in neurological disorders.
@en
P2093
Dorothea J Heersema
Jop P Mostert
Marco Heerings
P2860
P304
P356
10.1111/J.1527-3458.2008.00040.X
P577
2008-01-01T00:00:00Z